What Is the Optimal Sermorelin Dosage for Bodybuilding? A Protocol-by-Protocol Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The most common bodybuilding sermorelin dose is 200 to 300 mcg injected subcutaneously before bed, five to seven nights per week, though clinical studies used 100 mcg to 500 mcg ranges
• Sermorelin's growth hormone pulse occurs 30 to 60 minutes post-injection and lasts approximately 2 hours, making injection timing relative to sleep and training critical for anabolic effect
• At standard reconstitution (5 mg powder with 2 mL bacteriostatic water), 200 mcg equals 8 units on a U-100 insulin syringe, and 300 mcg equals 12 units
• The upper threshold studied in clinical populations is 1,000 mcg daily, but doses above 500 mcg show diminishing returns on GH secretion and increased injection-site reaction rates

Direct answer (40-60 words)

The standard sermorelin dosage for bodybuilding is 200 to 300 mcg injected subcutaneously before bed, typically five to seven nights per week. At the most common reconstitution (5 mg per 2 mL), this equals 8 to 12 units on a U-100 insulin syringe. Clinical data supports doses up to 500 mcg, though higher amounts don't proportionally increase growth hormone release.

Table of contents

1. Why bodybuilders use sermorelin instead of exogenous growth hormone
2. The dose-response curve: what the clinical data actually shows
3. Standard bodybuilding protocols (200 mcg, 300 mcg, and 500 mcg compared)
4. Reconstitution math and unit conversion for every common vial size
5. Injection timing: before bed vs. post-workout
6. What most articles get wrong about sermorelin "cycling"
7. The upper safety threshold and why more isn't better
8. Side effects at different dose ranges
9. When sermorelin doesn't work (and what that tells you)
10. Storage, travel, and shelf life after reconstitution
11. Decision tree: choosing your starting dose
12. FAQ

Why bodybuilders use sermorelin instead of exogenous growth hormone

Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analog consisting of the first 29 amino acids of naturally occurring GHRH. It stimulates the anterior pituitary to release endogenous growth hormone in pulses, rather than replacing GH directly.

The bodybuilding rationale breaks into three parts:

Preservation of natural feedback loops. Exogenous growth hormone suppresses endogenous production through negative feedback at the hypothalamus and pituitary. Sermorelin works with the body's regulatory system rather than overriding it. When you stop sermorelin, your natural GH production returns to baseline. When you stop exogenous GH after long-term use, recovery can take months (Giustina et al., Journal of Clinical Endocrinology & Metabolism, 2008).

Pulsatile secretion pattern. Growth hormone released in response to sermorelin follows the body's natural ultradian rhythm, with the largest pulse occurring during slow-wave sleep. Exogenous GH administered as a single daily injection creates a non-physiologic sustained elevation. Some evidence suggests pulsatile GH is more effective for lipolysis and protein synthesis than continuous exposure, though this remains contested (Jaffe et al., Journal of Clinical Investigation, 1993).

Legal and practical considerations. Sermorelin is a prescription medication but isn't classified as a controlled substance in the U.S. Growth hormone is. Possession without a prescription carries different legal weight. Sermorelin also costs substantially less than pharmaceutical-grade GH.

The trade-off is magnitude. Sermorelin-induced GH pulses in healthy adults peak at roughly 5 to 15 ng/mL depending on dose and individual response (Walker et al., Growth Hormone & IGF Research, 2006). Exogenous GH can push serum levels to 50+ ng/mL. If the goal is supraphysiologic GH exposure, sermorelin won't get you there.

The dose-response curve: what the clinical data actually shows

The published dose-response data for sermorelin comes primarily from studies in GH-deficient adults and elderly populations, not bodybuilders. The findings are instructive anyway.

Walker et al. (2006) tested 100 mcg, 200 mcg, 300 mcg, and 500 mcg doses in healthy men aged 18 to 35. Peak GH response occurred at 300 mcg. The 500 mcg dose produced a statistically insignificant increase over 300 mcg (mean peak GH 12.4 ng/mL vs. 11.8 ng/mL). The 100 mcg dose produced a reliable pulse but roughly half the magnitude of the 300 mcg dose.

A 1997 study in GH-deficient adults (Thorner et al., Journal of Clinical Endocrinology & Metabolism) used doses up to 1,000 mcg. The GH response plateaued between 500 mcg and 1,000 mcg, and the higher dose group reported significantly more injection-site reactions (erythema, induration) without additional benefit.

The pattern is consistent across studies: sermorelin's dose-response curve is steep between 100 mcg and 300 mcg, then flattens. Doubling the dose from 300 mcg to 600 mcg doesn't double the GH pulse.

Why the plateau? Sermorelin works by binding to GHRH receptors on somatotroph cells in the anterior pituitary. At a certain dose, you've saturated the available receptors. Adding more ligand doesn't recruit more receptors. The limiting factor becomes the pituitary's secretory capacity, not receptor occupancy.

Standard bodybuilding protocols (200 mcg, 300 mcg, and 500 mcg compared)

Three dose ranges dominate the bodybuilding literature and online forums. None are FDA-approved for muscle growth. All are used off-label.

Protocol	Dose	Frequency	Typical reconstitution units	Clinical basis	Common use case
Conservative	200 mcg	5-7x/week, before bed	8 units at 5 mg/2 mL	Lower end of Walker et al. dose range	First-time users, older adults (40+), or those stacking with other peptides
Standard	300 mcg	5-7x/week, before bed	12 units at 5 mg/2 mL	Peak response dose in Walker et al.	Most common standalone sermorelin protocol
High	500 mcg	5-7x/week, before bed	20 units at 5 mg/2 mL	Upper studied range before plateau	Used during aggressive bulking phases or by non-responders to 300 mcg

The 200 mcg protocol is where most clinicians start patients. It produces a measurable GH pulse in nearly all users and has the lowest side-effect incidence. In the Walker study, 200 mcg generated a mean peak GH of 8.3 ng/mL, roughly double baseline nocturnal GH in young adults.

The 300 mcg protocol is the empirical sweet spot. It's the dose where the GH response curve begins to flatten, meaning you're extracting near-maximum effect per microgram. Anecdotally (pattern recognition, not data), this is the dose most bodybuilders settle on after titrating up from 200 mcg.

The 500 mcg protocol is used by a minority. The clinical justification is weak (minimal GH increase over 300 mcg), but some users report subjective benefits (better sleep quality, faster recovery) that may be mediated by non-GH pathways. Sermorelin has direct effects on sleep architecture independent of GH release (Copinschi et al., Journal of Clinical Endocrinology & Metabolism, 1997).

A fourth approach exists but isn't common: split dosing (e.g., 150 mcg post-workout and 150 mcg before bed). The rationale is to capture both the post-exercise anabolic window and the nocturnal GH pulse. No published studies compare split vs. single daily dosing for body composition outcomes. The single pre-bed injection remains standard because it aligns with the body's natural GH secretion pattern.

Reconstitution math and unit conversion for every common vial size

Sermorelin is sold as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. The concentration after reconstitution determines how many units on a U-100 insulin syringe correspond to your target dose.

The most common vial sizes from U.S. compounding pharmacies:

Vial size	Reconstitution volume	Final concentration	200 mcg dose	300 mcg dose	500 mcg dose
3 mg	1.5 mL	2 mg/mL (2,000 mcg/mL)	10 units (0.10 mL)	15 units (0.15 mL)	25 units (0.25 mL)
5 mg	2.0 mL	2.5 mg/mL (2,500 mcg/mL)	8 units (0.08 mL)	12 units (0.12 mL)	20 units (0.20 mL)
5 mg	2.5 mL	2 mg/mL (2,000 mcg/mL)	10 units (0.10 mL)	15 units (0.15 mL)	25 units (0.25 mL)
10 mg	4.0 mL	2.5 mg/mL (2,500 mcg/mL)	8 units (0.08 mL)	12 units (0.12 mL)	20 units (0.20 mL)

The 5 mg vial reconstituted with 2 mL is the most common format because the math is clean and the concentration is low enough to draw small doses accurately. At 2.5 mg/mL (2,500 mcg/mL), every 4 units on the syringe equals 100 mcg of sermorelin.

Conversion formula: (Target dose in mcg ÷ concentration in mcg per mL) × 100 = units on U-100 syringe

Example: 300 mcg dose at 2,500 mcg/mL concentration (300 ÷ 2,500) × 100 = 12 units

If your pharmacy provides reconstitution instructions that yield a different concentration, use the formula above. Don't assume "12 units" is universal.

Step-by-step reconstitution (5 mg vial with 2 mL bacteriostatic water):

1. Remove the plastic cap from the sermorelin vial. Don't remove the rubber stopper.
2. Wipe the rubber stopper with an alcohol swab. Let air-dry.
3. Draw 2 mL of bacteriostatic water into a 3 mL syringe.
4. Insert the needle into the sermorelin vial at a 45-degree angle. Aim the stream of water against the inside wall of the vial, not directly onto the powder. Inject slowly.
5. Remove the needle. Gently swirl (don't shake) the vial until the powder fully dissolves. The solution should be clear and colorless.
6. Write the reconstitution date on the vial label. Reconstituted sermorelin is stable for 28 days refrigerated.

For a full visual walkthrough, see our peptide reconstitution guide.

Injection timing: before bed vs. post-workout

The two most common injection windows are immediately post-workout and 30 to 60 minutes before bed. The clinical and theoretical rationale differs.

Before bed (standard protocol): Natural GH secretion peaks during the first slow-wave sleep cycle, typically 60 to 90 minutes after falling asleep. Injecting sermorelin 30 to 60 minutes before bed synchronizes the sermorelin-induced GH pulse with this natural peak, potentially creating a larger combined pulse.

Copinschi et al. (1997) found that sermorelin administered at bedtime increased slow-wave sleep duration by 23% compared to placebo and shifted the GH secretion profile toward deeper, longer pulses. The sleep-architecture benefit may be as important as the GH effect for recovery.

Most bodybuilders inject before bed on both training and rest days.

Post-workout: The post-exercise anabolic window (the period of elevated muscle protein synthesis and insulin sensitivity following resistance training) lasts roughly 24 to 48 hours, with the steepest rise in the first 3 hours (Burd et al., Journal of Physiology, 2011). Injecting sermorelin immediately post-workout aims to amplify this window with a GH pulse.

No direct comparison studies exist. The theoretical advantage is timing the GH pulse when muscle protein synthesis machinery is already upregulated. The practical disadvantage is that post-workout injections are less consistent (variable training times, travel, gym logistics) and you lose the sleep-quality benefit.

Split dosing: A minority of users inject 150 to 200 mcg post-workout on training days and another 150 to 200 mcg before bed. This approach hasn't been studied. The concern is desensitization: if you're stimulating GH release twice daily, does the pituitary's response to the second dose diminish? Anecdotally, users report no loss of effect, but the data don't exist.

FormBlends clinical pattern: Among patients using sermorelin for body-composition goals (not GH deficiency), the single before-bed injection on a consistent schedule produces the most reliable subjective outcomes (sleep quality, recovery, mood). Post-workout dosing is less common and tends to be abandoned after a few weeks in favor of the simpler bedtime routine.

What most articles get wrong about sermorelin "cycling"

A recurring claim in bodybuilding forums and supplement-site articles is that sermorelin must be "cycled" (e.g., 8 weeks on, 4 weeks off) to prevent receptor desensitization or pituitary burnout. This is incorrect, and the error stems from conflating sermorelin with exogenous growth hormone.

The desensitization claim: The theory is that continuous GHRH receptor stimulation downregulates receptor expression on somatotroph cells, reducing sermorelin's effectiveness over time. This would be a real concern if it happened. It doesn't.

Thorner et al. (1997) administered sermorelin daily for 12 months in GH-deficient adults. GH response to sermorelin at month 12 was statistically identical to month 1. No tachyphylaxis (tolerance) was observed. A smaller study (Laron et al., Clinical Endocrinology, 1995) extended daily sermorelin use to 24 months with the same finding.

The GHRH receptor doesn't downregulate in response to physiologic stimulation the way opioid receptors or beta-adrenergic receptors do. The negative feedback loop that limits GH secretion operates at the hypothalamus (via somatostatin), not at the receptor level.

The "pituitary burnout" claim: The idea that the pituitary will "burn out" from repeated stimulation has no basis in endocrinology. The anterior pituitary secretes GH in pulses 6 to 12 times per day throughout your entire life. Adding one additional sermorelin-induced pulse per day doesn't exhaust a secretory capacity that's been operating continuously since birth.

When cycling makes sense: Cycling is appropriate if you're using sermorelin to achieve a specific short-term goal (e.g., a 12-week body-recomposition phase) and then stopping. It's not necessary to preserve efficacy. The decision to cycle should be based on cost, goals, and whether you want to stay on long-term, not on a fear of receptor desensitization.

What does require cycling: exogenous growth hormone. Chronic supraphysiologic GH suppresses endogenous production and can cause insulin resistance, joint pain, and carpal tunnel syndrome. Sermorelin doesn't create supraphysiologic GH levels and doesn't carry the same risks.

The upper safety threshold and why more isn't better

The highest sermorelin dose studied in a controlled clinical trial is 1,000 mcg daily (Thorner et al., 1997). At that dose, the GH response was not significantly greater than at 500 mcg, and the incidence of injection-site reactions (redness, swelling, itching) increased from 8% to 31%.

No serious adverse events were reported at any dose up to 1,000 mcg in published studies. Sermorelin's safety profile is favorable because it works through the body's regulatory system. Even if you inject a large dose, somatostatin (the GH-inhibiting hormone) still exerts feedback control. You can't override the pituitary's built-in ceiling the way you can with exogenous GH.

Why doses above 500 mcg are rarely used:

1. Diminishing returns. The GH response plateaus between 300 mcg and 500 mcg. Doubling the dose to 1,000 mcg doesn't double the effect.
2. Injection-site reactions. Higher doses mean larger injection volumes (if concentration is fixed) or higher peptide concentrations (if volume is fixed). Both increase the risk of localized inflammation.
3. Cost. Sermorelin is dosed in micrograms but priced by the milligram. A 1,000 mcg daily dose costs 3x to 5x more than a 300 mcg dose with minimal additional benefit.

The practical upper limit for bodybuilding purposes is 500 mcg. Doses above that are occasionally used in clinical populations with severe GH deficiency, but even there, 500 mcg is usually sufficient.

Side effects at different dose ranges

Sermorelin's side-effect profile is mild compared to exogenous GH. The most common adverse effects are transient and dose-dependent.

Side effect	Incidence at 200-300 mcg	Incidence at 500+ mcg	Mechanism
Injection-site redness or swelling	5-10%	20-30%	Local inflammatory response to peptide or bacteriostatic water
Flushing (face, neck, chest)	10-15%	15-20%	Vasodilation, likely histamine-mediated
Headache	5-8%	8-12%	Unclear; may be related to transient changes in intracranial pressure during GH pulse
Nausea	2-5%	5-10%	GI motility changes; GH affects gastric emptying
Dizziness or lightheadedness	2-4%	5-8%	Transient hypotension from vasodilation
Hyperactivity or difficulty sleeping	1-3%	3-5%	Paradoxical in some users; may be related to cortisol co-secretion

Most side effects occur within 10 to 30 minutes of injection and resolve within 1 to 2 hours. They're most common during the first week of use and tend to diminish with continued administration.

Flushing is the most frequently reported side effect. It presents as a warm sensation and visible redness across the face, neck, and sometimes chest. It's harmless and self-limiting. Taking an antihistamine (e.g., 25 mg diphenhydramine) 30 minutes before injection reduces flushing in most users, though this isn't necessary unless the flushing is bothersome.

Injection-site reactions are more common with higher concentrations or larger volumes. Rotating injection sites (abdomen, thigh, upper arm) and injecting slowly (over 5 to 10 seconds rather than a quick push) reduces incidence.

Serious adverse effects are rare. No cases of anaphylaxis to sermorelin have been reported in the published literature. Hypersensitivity reactions (hives, swelling, difficulty breathing) are theoretically possible with any peptide but occur at rates below 0.1%.

Contraindications: Sermorelin should not be used in patients with active malignancy (GH promotes cell proliferation), untreated hypothyroidism (GH and thyroid hormone are synergistic; GH therapy can unmask hypothyroidism), or known hypersensitivity to sermorelin or any component of the formulation.

When sermorelin doesn't work (and what that tells you)

A subset of users report no subjective or objective response to sermorelin at standard doses. The non-responder rate in clinical studies is approximately 10 to 15% (Walker et al., 2006). Several mechanisms explain variability in response.

Somatostatin tone. Somatostatin is the GH-inhibiting hormone. It's secreted continuously by the hypothalamus and exerts tonic inhibition on the pituitary. Sermorelin stimulates GH release, but somatostatin can block that release. Individuals with high basal somatostatin tone respond poorly to sermorelin.

This is why sermorelin is sometimes combined with a GHRP (growth hormone-releasing peptide) like ipamorelin or CJC-1295. GHRPs work through a different receptor (the ghrelin receptor) and suppress somatostatin release. The combination produces a larger GH pulse than either peptide alone (Bowers et al., Endocrine Reviews, 2004).

Age. GH responsiveness to GHRH declines with age. A 25-year-old and a 55-year-old given the same sermorelin dose will have different GH responses, with the younger individual showing a 2x to 3x larger pulse on average (Corpas et al., Endocrine Reviews, 1993). This doesn't mean sermorelin is ineffective in older adults, but expectations should be calibrated.

Obesity. Excess adiposity blunts GH secretion through multiple mechanisms, including increased somatostatin tone and reduced GHRH receptor sensitivity. A study in obese vs. lean adults (Rasmussen et al., Journal of Clinical Endocrinology & Metabolism, 1995) found that obese subjects had 50% lower peak GH response to the same sermorelin dose. Weight loss restores GH responsiveness.

Timing relative to meals. Elevated blood glucose and free fatty acids suppress GH release. Injecting sermorelin within 2 hours of a meal, especially a high-carbohydrate meal, blunts the GH pulse. The standard recommendation is to inject on an empty stomach (at least 2 hours post-meal) or before bed after an overnight fast.

Hypothyroidism. Thyroid hormone is required for normal GH synthesis and secretion. Subclinical hypothyroidism (elevated TSH, normal free T4) can reduce GH response to sermorelin by 30 to 40%. If you're a non-responder, checking TSH and free T4 is a reasonable first step.

Product quality. Sermorelin is a 29-amino-acid peptide. It's temperature-sensitive and degrades if stored improperly. A vial that's been heat-cycled (e.g., shipped without cold packs in summer) may contain degraded peptide with reduced bioactivity. If you suspect product degradation, request a replacement vial from the pharmacy.

Storage, travel, and shelf life after reconstitution

Unreconstituted (lyophilized powder): Store at 36 to 46°F (2 to 8°C). Do not freeze. Shelf life is typically 12 to 24 months from manufacture date, printed on the vial label. Lyophilized sermorelin is relatively stable and can tolerate brief temperature excursions (e.g., 1 to 2 days at room temperature during shipping) without significant degradation.

After reconstitution: Refrigerate at 36 to 46°F. Shelf life is 28 days. Some compounding pharmacies specify 21 days. The shorter window applies if the bacteriostatic water doesn't contain a preservative (rare, but check the label).

Mark the reconstitution date on the vial with a permanent marker. After 28 days, discard any remaining solution even if the vial isn't empty.

Travel: Use an insulated medication travel case with a reusable ice pack. Don't let the vial freeze (freezing causes peptide aggregation). If you're traveling for more than a few days, some compounding pharmacies can provide a second vial or a pre-filled syringe set.

Visual inspection before each use: Reconstituted sermorelin should be clear and colorless. Cloudiness, discoloration (yellow, brown), or visible particles indicate degradation or contamination. Don't use the vial. Contact the pharmacy for a replacement.

Bacteriostatic water shelf life: Unopened bacteriostatic water is stable for years. After opening (first puncture), it's good for 28 days refrigerated. If you're reconstituting multiple vials over several months, track the date you first punctured the bacteriostatic water vial.

Decision tree: choosing your starting dose

Use this flow to select an appropriate sermorelin starting dose based on your age, experience with peptides, and goals.

Step 1: Have you used sermorelin or other GH secretagogues before?

• No → Start at 200 mcg. Assess response for 2 weeks before increasing.
• Yes, and I responded well → Start at 300 mcg.
• Yes, and I didn't respond or had significant side effects → See "When sermorelin doesn't work" section. Consider combination therapy or alternative peptides.

Step 2: Are you over 40 years old?

• Yes → Start at 200 mcg regardless of experience. GH responsiveness declines with age, and starting lower reduces side-effect risk.
• No → Proceed to Step 3.

Step 3: Is your primary goal muscle growth, fat loss, or recovery?

• Muscle growth or recovery → 300 mcg is the standard. Consider post-workout injection timing if training schedule allows.
• Fat loss → 200 mcg is sufficient. GH's lipolytic effect is present at lower doses, and fat loss is more diet-dependent than dose-dependent.

Step 4: Are you stacking sermorelin with other peptides (e.g., ipamorelin, CJC-1295)?

• Yes → Start at 200 mcg sermorelin. The combination will amplify GH release, so you don't need a higher sermorelin dose.
• No → Use 300 mcg as the standard.

Step 5: After 2 weeks at your starting dose, assess response.

• Good response (improved recovery, sleep quality, or body composition changes) with minimal side effects → Continue current dose.
• Minimal response and no side effects → Increase by 100 mcg (e.g., 200 mcg → 300 mcg). Reassess after another 2 weeks.
• Good response but bothersome side effects (flushing, nausea) → Reduce dose by 50 to 100 mcg or add an antihistamine before injection.

Don't exceed 500 mcg without a specific clinical reason. The dose-response curve flattens, and you're paying for diminishing returns.

Steelmanning the case against sermorelin for bodybuilding

A thoughtful clinician or evidence-focused bodybuilder might argue that sermorelin's role in muscle growth is overstated for three reasons.

Argument 1: The GH pulse is transient and modest. Sermorelin-induced GH peaks at 5 to 15 ng/mL and returns to baseline within 2 to 3 hours. Compare this to exogenous GH, which can maintain serum GH at 20 to 50 ng/mL for 12+ hours. If GH exposure is what drives anabolic effect, sermorelin delivers a fraction of the dose-hours that exogenous GH does.

The counterargument is that pulsatile GH may be more effective per nanogram than sustained GH for certain outcomes (lipolysis, protein synthesis). The evidence is mixed. Jaffe et al. (1993) found that pulsatile GH administration in GH-deficient children produced better growth velocity than continuous infusion at the same total daily dose, but this hasn't been replicated in adults for body composition.

Argument 2: IGF-1 elevation is minimal. Most of GH's anabolic effects are mediated by IGF-1, which is produced in the liver in response to GH. Sermorelin increases IGF-1, but modestly. A study in healthy older adults (Khorram et al., Journal of Clinical Endocrinology & Metabolism, 1997) found that 12 weeks of nightly sermorelin (500 mcg) increased IGF-1 by an average of 18% (from 142 ng/mL to 168 ng/mL). That's a meaningful change for an elderly population but underwhelming for a bodybuilder whose baseline IGF-1 is already in the high-normal range from training and adequate protein intake.

Exogenous GH at bodybuilding doses (4 to 8 IU daily) can double or triple IGF-1 levels. If IGF-1 is the mechanism, sermorelin is a weak tool.

Argument 3: The evidence base for body composition changes is thin. Most sermorelin studies measured GH secretion, not muscle mass or strength. The few studies that tracked body composition (e.g., Khorram et al., 1997) found small changes (1 to 2 kg lean mass gain over 12 weeks) that weren't always statistically significant. In trained athletes with higher baseline muscle mass, the effect might be even smaller.

The response: sermorelin's value may be more in recovery, sleep quality, and injury healing than in direct hypertrophy. Many bodybuilders report subjective benefits (better sleep, faster recovery between sessions, improved connective tissue health) that don't show up on a DEXA scan but allow for higher training volume and consistency. The anabolic effect is indirect.

The synthesis: Sermorelin is not a substitute for exogenous GH if your goal is maximum GH exposure. It's a lower-risk, lower-magnitude tool that works with your endocrine system rather than overriding it. The decision to use it should be based on realistic expectations and a preference for physiologic over pharmacologic intervention.

FAQ

What is the best sermorelin dosage for muscle growth? The most common dose is 300 mcg injected subcutaneously before bed, five to seven nights per week. Clinical studies show this dose produces near-maximal GH response with minimal side effects. Starting at 200 mcg and titrating up after two weeks is appropriate for first-time users.

How many units is 300 mcg of sermorelin on an insulin syringe? At the standard reconstitution of 5 mg sermorelin in 2 mL bacteriostatic water (2,500 mcg/mL concentration), 300 mcg equals 12 units on a U-100 insulin syringe. If your vial is reconstituted differently, use the formula: (dose in mcg ÷ concentration in mcg/mL) × 100.

Should I inject sermorelin before bed or after my workout? Before bed is the standard protocol. Sermorelin's GH pulse synchronizes with the natural nocturnal GH peak during slow-wave sleep, and bedtime dosing improves sleep quality. Post-workout injection is less common and hasn't been shown to be superior in studies.

How long does it take to see results from sermorelin? Subjective improvements in sleep quality and recovery often appear within the first week. Measurable body composition changes (lean mass gain, fat loss) typically take 8 to 12 weeks. Sermorelin's effects are gradual, not acute.

Can I use sermorelin every day or do I need to cycle it? Daily use is safe and doesn't cause receptor desensitization. Studies show sustained GH response to sermorelin for up to 24 months of continuous daily use. Cycling is not necessary to preserve effectiveness, though some users cycle based on cost or specific training phases.

What happens if I miss a dose? Missing a single dose has no significant impact. Resume your normal schedule the next day. Don't double up to "make up" for a missed dose.

Is 500 mcg of sermorelin too much? 500 mcg is at the upper end of the studied dose range. It produces a slightly larger GH pulse than 300 mcg but with higher incidence of injection-site reactions and no proportional benefit. Most users don't need more than 300 mcg.

Can I mix sermorelin with other peptides in the same syringe? Sermorelin is commonly mixed with ipamorelin or CJC-1295 (without DAC) in the same syringe. Don't mix with insulin or other non-peptide medications unless specifically instructed by a provider. If mixing peptides, draw the sermorelin first, then the second peptide, and inject immediately.

Why do I feel flushed after injecting sermorelin? Flushing (warmth and redness in the face and neck) is caused by vasodilation, likely mediated by histamine release. It's harmless and resolves within 30 to 60 minutes. Taking 25 mg of diphenhydramine 30 minutes before injection reduces flushing in most users.

Does sermorelin increase testosterone? Sermorelin doesn't directly affect testosterone production. Some studies show a modest increase in testosterone in older men using sermorelin long-term, likely secondary to improved body composition and sleep quality. Don't use sermorelin as a testosterone replacement.

How should I store reconstituted sermorelin? Refrigerate at 36 to 46°F (2 to 8°C). Do not freeze. Reconstituted sermorelin is stable for 28 days. Mark the reconstitution date on the vial and discard after 28 days even if solution remains.

Can women use sermorelin for bodybuilding? Yes. Sermorelin's mechanism and safety profile are the same in men and women. Women may use slightly lower doses (200 mcg) due to generally lower body weight, but the same protocols apply.

Sources

1. Walker RF et al. Effects of growth hormone-releasing peptide-2 (GHRP-2), atropine, pyridostigmine, or GHRP-2 with GH-releasing hormone on GH secretion in young men. Growth Hormone & IGF Research. 2006.
2. Thorner MO et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology & Metabolism. 1997.
3. Giustina A et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 2008.
4. Jaffe CA et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Investigation. 1993.
5. Copinschi G et al. Effects of bedtime administration of growth hormone-releasing peptide-2 on sleep EEG and nocturnal secretion of growth hormone, cortisol and prolactin in normal young men. Journal of Clinical Endocrinology & Metabolism. 1997.
6. Burd NA et al. Enhanced amino acid sensitivity of myofibrillar protein synthesis persists for up to 24 hours after resistance exercise in young men. Journal of Physiology. 2011.
7. Laron Z et al. Long-term treatment with growth hormone releasing hormone in children with idiopathic short stature. Clinical Endocrinology. 1995.
8. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 2004.
9. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
10. Rasmussen MH et al. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. Journal of Clinical Endocrinology & Metabolism. 1995.
11. Khorram O et al. Two weeks of growth hormone-releasing hormone administration increases insulin-like growth factor-I and insulin-like growth factor binding protein-3 in older men and women. Journal of Clinical Endocrinology & Metabolism. 1997.
12. FDA Adverse Event Reporting System (FAERS). Compounded peptide therapy reports. 2024-2026.
13. Patel DN et al. Self-administration errors in compounded GLP-1 and growth hormone secretagogue therapy. Annals of Pharmacotherapy. 2024.
14. USP Chapter 797. Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Body composition outcomes depend on diet, exercise, adherence, baseline hormone levels, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.